Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
PHVS compared with MNPR: revenue, margins and what each company keeps, and the suppliers and customers both name
PHVS
Pharvaris N.V.
Change
Mkt cap
Revenue
Revenue
MNPR
Monopar Therapeutics
Change
Mkt cap
Revenue
Revenue
vs
Compare
PHVS
Pharvaris N.V.
vs
MNPR
Monopar Therapeutics
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
PHVS, solid
MNPR, dashed
Supply-chain overlap
Revenue flow
PHVS: latest quarter not drawable. MNPR: latest quarter not drawable.
Method
›
PHVS
Pharvaris N.V.
Change
33.53
▼
−0.13%
· post 34.68
Mkt cap
$2.2B
MNPR
Monopar Therapeutics
Change
69.99
▼
−2.66%
· post 69.99
Closed
Oct 30 '26
Mkt cap
$472.0M
vs
Compare
Closed
Oct 30 '26
PHVS
Pharvaris N.V.
vs
MNPR
Monopar Therapeutics
33.53
▼
−0.13%
post 34.68
Price
69.99
▼
−2.66%
post 69.99
$2.2B
Mkt cap
$472.0M
Change
Change
PHVS
33.53
▼
−0.13%
vs
MNPR
69.99
▼
−2.66%
Closed
Oct 30 '26
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only PHVS
1
—
Brain
unlisted
supplier
Shared
0
No shared counterparties.
Only MNPR
2
AZN
AstraZeneca
supplier
—
NorthStar
unlisted
supplier
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR